Posted by Michael Wonder on 03 Aug 2016
Nivolumab in renal cell carcinoma: indication of additional clinical benefits
1 August 2016 - Benefits in overall survival, morbidity and side effects.
Nivolumab (Opdivo) has been available since April 2016 for the treatment of adults with advanced renal cell carcinoma who have undergone previous therapy. In an early benefit assessment, the IQWiG has investigated whether nivolumab provides an additional clinical benefit over the appropriate comparator therapy in these patients.
There is indication of a considerable additional clinical benefit in patients with a poor prognosis. For patients with favorable or intermediate prognosis, the additional clinical benefit is considerable.
